Table 2.
Subgroup analysis of pooled estimates of seizure response.
| Subgroup | No. of studies | Mean | 95% CI | p-value between subgroups |
|---|---|---|---|---|
| Drug | ||||
| Lacosamide | 7 | 66% | 0.57–0.74 | 0.04 |
| Perampanel | 6 | 78% | 0.64–0.87 | |
| Eslicarbazepine acetate | 1 | 75% | 0.35–0.97 | |
| Brivaracetam | 1 | 61% | 0.42–0.77 | |
| Clobazam | 1 | 94% | 0.80–0.99 | |
| Brain tumor type | ||||
| Primary brain tumor | 14 | 71% | 0.62–0.79 | 0.9 |
| Primary and metastases brain tumor | 4 | 73% | 0.54–0.86 | |
| Epilepsy type | ||||
| BTRE | 9 | 69% | 0.60–0.77 | 0.54 |
| Uncontrolled seizures | 8 | 74% | 0.60–0.85 | |
| Concomitant or not | ||||
| Concomitant | 13 | 75% | 0.65–0.82 | 0.03 |
| Non-concomitant | 4 | 61% | 0.64–0.78 | |